Trastuzumab: A Picky Partner?MCARTHUR, Heather L; HUDIS, Clifford A.Clinical cancer research (Print). 2009, Vol 15, Num 20, pp 6311-6313, issn 1078-0432, 3 p.Article

Preclinical characterisation of ¹¹¹In-DTPA-trastuzumabLUB-DE HOOGE, Marjolijn N; KOSTERINK, Jos G. W; PERIK, Patrick J et al.British journal of pharmacology. 2004, Vol 143, Num 1, pp 99-106, issn 0007-1188, 8 p.Article

Herceptin-geldanamycin immunoconjugates: Pharmacokinetics, biodistribution, and enhanced antitumor activityMANDLER, Raya; KOBAYASHI, Hisataka; HINSON, Ella R et al.Cancer research (Baltimore). 2004, Vol 64, Num 4, pp 1460-1467, issn 0008-5472, 8 p.Article

Biological therapy of salivary duct carcinomaNASHED, M; CASASOLA, R. J.Journal of laryngology and otology. 2009, Vol 123, Num 2, pp 250-252, issn 0022-2151, 3 p.Article

Reversibility of Trastuzumab Cardiotoxicity : Is the Concept Alive and Well?EWER, Michael S; TAN-CHIU, Elizabeth; TELLI, Melinda L et al.Journal of clinical oncology. 2007, Vol 25, Num 34, pp 5532-5534, issn 0732-183X, 3 p.Article

From the trastuzumab era to new target therapies : beyond revolutionBARNI, S; PETRELLI, F; CABIDDU, M et al.Annals of oncology. 2007, Vol 18, issn 0923-7534, vi1-vi4, SUP6Conference Paper

Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasmaJAMIESON, David; CRESTI, Nicola; VERRILL, Mark W et al.Journal of immunological methods. 2009, Vol 345, Num 1-2, pp 106-111, issn 0022-1759, 6 p.Article

Concomitant trastuzumab with thoracic radiotherapy: a morphological and functional studyYAVAS, G; YILDIZ, F; GULER, S et al.Annals of oncology. 2011, Vol 22, Num 5, pp 1120-1126, issn 0923-7534, 7 p.Article

Future options with trastuzumab for primary systemic and adjuvant therapyBASELGA, José; GIANNI, Luca; GEYER, Charles et al.Seminars in oncology. 2004, Vol 31, Num 5, pp 51-57, issn 0093-7754, 7 p., SUP10Article

Plant-Produced Trastuzumab Inhibits the Growth of HER2 Positive Cancer CellsGROHS, Brittany M; YONGQING NIU; VELDHUIS, Linda J et al.Journal of agricultural and food chemistry (Print). 2010, Vol 58, Num 18, pp 10056-10063, issn 0021-8561, 8 p.Article

Trastuzumab-Induced HepatotoxicitySRINIVASAN, Sridhar; PARSA, Venkata; LIU, Chin Y et al.The Annals of pharmacotherapy. 2008, Vol 42, Num 10, pp 1497-1501, issn 1060-0280, 5 p.Article

Adjuvant Trastuzumab Induces Ventricular Remodeling Despite Aerobic Exercise TrainingHAYKOWSKY, Mark J; MACKEY, John R; THOMPSON, Richard B et al.Clinical cancer research (Print). 2009, Vol 15, Num 15, pp 4963-4967, issn 1078-0432, 5 p.Article

Clinical cardiac tolerability of trastuzumabPEREZ, Edith A; RODEHEFFER, Richard.Journal of clinical oncology. 2004, Vol 22, Num 2, pp 322-329, issn 0732-183X, 8 p.Article

Management of Trastuzumab-Related Cardiac DysfunctionCARVER, Joseph R.Progress in cardiovascular diseases. 2010, Vol 53, Num 2, pp 130-139, issn 0033-0620, 10 p.Article

Trastuzumab before breast surgery: is concurrent administration with anthracycline-containing chemotherapy necessary?DEL MASTRO, L; BIGHIN, C; BINI, G et al.Annals of oncology. 2010, Vol 21, Num 6, pp 1376-1377, issn 0923-7534, 2 p.Article

Reproducibility of [¹¹C]Choline-Positron Emission Tomography and Effect of TrastuzumabKENNY, Laura M; CONTRACTOR, Kaiyumars B; HINZ, Rainer et al.Clinical cancer research (Print). 2010, Vol 16, Num 16, pp 4236-4245, issn 1078-0432, 10 p.Article

Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific T cytotoxic lymphocytesKONO, Koji; SATO, Eiji; NAGANUMA, Hirofumi et al.Clinical cancer research. 2004, Vol 10, Num 7, pp 2538-2544, issn 1078-0432, 7 p.Article

High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)―mediated inhibition of platelet productionTHON, Jonathan N; DEVINE, Matthew T; JURAK BEGONJA, Antonija et al.Blood. 2012, Vol 120, Num 10, pp 1975-1984, issn 0006-4971, 10 p.Article

Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I EvaluationCARDINALE, Daniela; COLOMBO, Alessandro; NOLE, Franco et al.Journal of clinical oncology. 2010, Vol 28, Num 25, pp 3910-3916, issn 0732-183X, 7 p.Article

Contact spotting of protein microarrays coupled with spike-in of normalizer protein permits time-resolved analysis of ERBB receptor signalingLÖBKE, Christian; LAIBLE, Mark; RAPPL, Claudia et al.Proteomics (Weinheim. Print). 2008, Vol 8, Num 8, pp 1586-1594, issn 1615-9853, 9 p.Article

Synergistic interactions between tamoxifen and trastuzumab (Herceptin)ARGIRIS, Athanassios; WANG, Chun-Xia; WHALEN, Steve G et al.Clinical cancer research. 2004, Vol 10, Num 4, pp 1409-1420, issn 1078-0432, 12 p.Article

HER2/neu as a Potential Target for Immunotherapy in Gynecologic CarcinosarcomasGUZZO, Federica; BELLONE, Stefania; SCHWARTZ, Peter E et al.International journal of gynecological pathology. 2012, Vol 31, Num 3, pp 211-221, issn 0277-1691, 11 p.Article

Expression of tyrosine kinase receptors in Malignant midgut carcinoid tumorsWELIN, Staffan; FJÄLLSKOG, Marie Louise; SARAS, Jan et al.Neuroendocrinology (Basel). 2006, Vol 84, Num 1, pp 42-48, issn 0028-3835, 7 p.Article

Monoclonal antibody-polyethyleneimine conjugates targeting Her-2/neu or CD90 allow cell type-specific nonviral gene deliverySTREHBLOW, Claudia; SCHUSTER, Maj; MORITZ, Thomas et al.Journal of controlled release. 2005, Vol 102, Num 3, pp 737-747, issn 0168-3659, 11 p.Article

Toxicité cardiaque d'une nouvelle chimiothérapie anticancéreuse: le trastuzumab (Herceptin): D'un effet indésirable vers un modèle expérimental d'insuffisance cardiaque = Cardiac toxicity of a new oncological chemotherapy: trastuzumab (Herceptin)FERRARI, E; BENHAMOU, M; BAUDOUY, M et al.Archives des maladies du coeur et des vaisseaux. 2004, Vol 97, Num 4, pp 333-337, issn 0003-9683, 5 p.Article